高级检索
当前位置: 首页 > 详情页

The efficacy and safety of 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. [2]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Southwest Medical University, Luzhou, Sichuan, China. [3]Laboratory for Targeted Radiopharmaceuticals Creation, Southwest Medical University, Luzhou, Sichuan, China. [4]Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China.
出处:
ISSN:

关键词: prostate cancer 225 Ac-PSMA-617 radioligand therapy 68 Ga-PSMA PET/CT

摘要:
We aimed to report our clinical experience with the use of 225Ac-PSMA-617 in the treatment of mCRPC patients.A retrospective analysis was conducted on 29 metastatic castration-resistant prostate cancer (mCRPC) patients treated with 225Ac-PSMA-617. Patients underwent treatment at 8-week intervals and discontinued treatment upon disease progression or the occurrence of intolerable adverse effects. We acquired 68Ga-PSMA-11 PET/CT images and laboratory test outcomes of patients at baseline and 8 weeks following each treatment. Short-term efficacy was evaluated through the biochemical response of serum prostate-specific antigen (PSA) and molecular tumor response criteria. A follow-up was conducted to assess the long-term effectiveness by examining the patient's overall survival (OS) and progression-free survival (PFS). The numerical rating scale (NRS) assessed the patient's pain. The side effects after treatment were evaluated based on common terminal criteria for adverse events version 5.0 (CTCAE v5.0).29 patients with mCRPC underwent a total of 50 treatment cycles. The median age of the patients was 67 years (55-84years). Out of these patients, 11 had previously underwent 177 Lu-PSMA-617 radioligand therapy (RLT). After treatment, any PSA decline was observed in 75.9% of patients, and a PSA decline≥50% was observed in 62.1%. 61.1% of patients had disease control according to molecular response. The estimated OS and PFS were 18 months (95% CI: 15-21 months) and 8 months (95% CI: 6-10 months). Univariate analysis showed that any PSA decline was positively correlated with PFS (p<0.001). The most common side effect was xerostomia, observed in 79.3% of patients. Grade III blood toxicity was observed in 7/29 patients. After treatment, the pain disappeared in 4 patients and was relieved in 13 individuals.In mCRPC, the results indicated that 225Ac-PSMA-617 demonstrated a favorable disease control rate and relatively minimal side effects. However, additional high-quality randomized controlled trials are required for future validation.Copyright © 2025 Ma, Zhang, Yangqing, Liu, Wang and Zhang.

语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
第一作者:
第一作者机构: [1]Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. [2]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Southwest Medical University, Luzhou, Sichuan, China. [3]Laboratory for Targeted Radiopharmaceuticals Creation, Southwest Medical University, Luzhou, Sichuan, China. [4]Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China.
通讯作者:
通讯机构: [1]Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. [2]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Southwest Medical University, Luzhou, Sichuan, China. [3]Laboratory for Targeted Radiopharmaceuticals Creation, Southwest Medical University, Luzhou, Sichuan, China. [4]Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:59671 今日访问量:0 总访问量:4873 更新日期:2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号